The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

Newly-launched obesity company Kailera Therapeutics has announced the appointment of Jamie Coleman as chief commercial ...

She joins Kailera from Eli Lilly where she held key roles in brand strategy, consumer marketing, and global commercial ...

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...

Lilly Investors have listed Zepbound for $1,086.37 per fill. But the actual costs will vary depending on each patient's insurance coverage of prescription drugs. Those who have commercial drug ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

A couple of months ago, healthcare equity research analyst Jared Holz from Mizuho spoke about Viking potentially being an acquisition target. During his discussion, Holz suggested that Viking could ...

Wegovy sales increased by more than 100% over 2024. But that wasn’t enough to satiate analysts who want to know why Novo Nordisk can’t access more patients, particularly in the U.S.

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...